CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 1. Flow cytometric analysis illustrating DNA and protein content at indicated time points in primary human T lymphocytes from a representative experiment. Top, cell cycle distributions of quiescent (Day 0 Untreated) and PHA-treated (Day 3 PHA), IL-2-treated (Day 6 IL-2), and IL-2-/IFN-{alpha}-treated (Day 6 IL-2+IFN-{alpha}) cells, determined by plotting the intensity of 4',6-diamidino-2-phenylindole propidium iodide fluorescence as a function of the cell number. Bottom, DNA and protein content in quiescent and PHA-, IL-2-, and IL-2-/IFN-{alpha}-treated cells, determined by plotting the intensity of 4',6-diamidino-2-phenylindole and SR101 fluorescence, respectively. Cells appearing in G2 in the quiescent (Day 0 Untreated), PHA-treated (Day 3 PHA), and IL-2-/IFN-{alpha}-treated (Day 6 IL-2+IFN-{alpha}) groups probably represent aggregated cells from G1 because no G2 cells were detected at these time points (top).





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation